Core Points - The inclusion of the HPV vaccine in the national immunization program is a significant step towards reducing the burden of cervical cancer in China and promoting public health [1][5][6] - The policy allows girls aged 13 and above, born after November 10, 2011, to receive two doses of the bivalent HPV vaccine for free, with a six-month interval between doses [5][6] - The initiative aims to improve vaccination rates and ensure equitable access to preventive services across different regions and income groups [5][6] Group 1 - The HPV vaccine serves as the first line of defense against cervical cancer, which is a common malignancy among women and poses serious health risks [5] - In 2022, approximately 151,000 new cases of cervical cancer were reported in China, with around 56,000 deaths attributed to the disease [5] - The decision to target 13-year-old girls for free vaccination is based on considerations of protection effectiveness, cost-effectiveness, and operational feasibility [5][6] Group 2 - The domestic production capacity for the bivalent HPV vaccine is estimated at 55 million doses annually, sufficient to meet market demand, with products certified by the World Health Organization [5][6] - The initiative reflects China's commitment to improving women's health and contributing to global health equity [6] - A comprehensive network is being established to ensure the effective implementation of the vaccination program, involving collaboration among multiple departments [6]